论文部分内容阅读
目的研究胃癌新辅助化疗疗效临床评价方法及进展。方法对有关胃癌新辅助化疗疗效临床评价方法的文献进行综述分析,比较CT、EUS、MRI及PET的评价结果与术后病理、预后结果的符合度。结果CT、EUS是目前临床中常用的疗效评价方法,但是其评价指标和标准不统一,胃癌套用现有的实体瘤疗效评价标准似乎并不适用;采用磁共振扩散加权成像(DWI)评价胃癌新辅助化疗疗效还有待进一步研究;PET在早期准确筛选出化疗无效病例方面具有优势。结论胃癌新辅助化疗疗效临床评价尚缺乏统一标准,各种影像学方法的综合应用可能有利于提高评价的准确性。
Objective To study the clinical evaluation of neoadjuvant chemotherapy in gastric cancer and its progress. Methods The literature review on the clinical evaluation of neoadjuvant chemotherapy for gastric cancer was reviewed. The results of CT, EUS, MRI and PET were compared with those of postoperative pathology and prognosis. Results CT and EUS were commonly used in clinical practice. However, the evaluation criteria and criteria of CT and EUS were not the same. The existing evaluation criteria for curative effect of solid tumors did not seem to be suitable for gastric cancer. The evaluation of gastric cancer by diffusion weighted imaging (DWI) The efficacy of adjuvant chemotherapy remains to be further studied; PET has advantages in accurately screening cases of ineffective chemotherapy in the early stage. Conclusion The clinical evaluation of neoadjuvant chemotherapy in gastric cancer lacks a uniform standard. The comprehensive application of various imaging methods may be helpful to improve the accuracy of evaluation.